Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors.
SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who
FuelCell Energy, Inc (NASDAQ: FCEL) has partnered with cloud computing and AI services provider International Business Machines Corporation (NYSE: IBM) to boost the performance of its technology using
U.S. stocks traded mixed toward the end of trading on Monday.
The Dow traded down 0.13% to 35,344.56 while the NASDAQ rose 0.11% to 14,266.69. The S&P 500 also fell, dropping, 0.08% to 4,555.47.